WASHINGTON, May 27, 2009 (GLOBE NEWSWIRE) -- Finkelstein Thompson LLP is currently investigating potential shareholder claims arising out of the acquisition of Cougar Biotechnologies, Inc. ("Cougar") (Nasdaq:CGRB) by Johnson & Johnson ("J&J") (NYSE:JNJ). Under the terms of the agreement, J&J, through a wholly owned subsidiary, will purchase all the outstanding shares of Cougar through a cash tender offer of $43 per share. The overall net value of the transaction is approximately $1 billion dollars.
The investigation is primarily focused on the potential unfairness of the merger price and of the process by which the Cougar Board of Directors approved the agreement.
If you are interested in discussing your rights as a Cougar shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at contact@finkelsteinthompson.com.
Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in connection with securities and other finance-related litigation, and has been appointed as lead or co-lead counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers. To learn more about Finkelstein Thompson LLP, please visit our web site at www.finkelsteinthompson.com.